The primary objective of this study is to determine whether a clinically significant PK drug
interaction ( a 30% difference in the AUC of MPA) exists between mycophenolate mofetil (under
steady state conditions) and VGCV in renal and cardiac transplant recipients.
This study will provide clinically relevant information to the transplant community. It will
more clearly delineate whether a clinically significant PK drug interaction exists between
mycophenolate mofetil (under steady-state conditions)and VGCV. Given the established
dose/efficacy relationship of both MMF and VGCV, this study will provide improved dosing
guidelines and potentially avoid adverse outcomes due to empiric dosage adjustments.